These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 23147542)
21. C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases. Pasoff M J Can Dent Assoc; 2013; 79():d51. PubMed ID: 23920073 [TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Sarasquete ME; González M; San Miguel JF; García-Sanz R Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677 [TBL] [Abstract][Full Text] [Related]
23. Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction. Bodem JP; Kargus S; Eckstein S; Saure D; Engel M; Hoffmann J; Freudlsperger C J Craniomaxillofac Surg; 2015 May; 43(4):510-4. PubMed ID: 25841311 [TBL] [Abstract][Full Text] [Related]
24. Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. Bagan J; Sáez GT; Tormos MC; Gavalda-Esteve C; Bagan L; Leopoldo-Rodado M; Calvo J; Camps C J Oral Pathol Med; 2014 May; 43(5):371-7. PubMed ID: 24450511 [TBL] [Abstract][Full Text] [Related]
25. Cell therapy in bisphosphonate-related osteonecrosis of the jaw. Gonzálvez-García M; Rodríguez-Lozano FJ; Villanueva V; Segarra-Fenoll D; Rodríguez-González MA; Oñate-Sánchez R; Blanquer M; Moraleda JM J Craniofac Surg; 2013 May; 24(3):e226-8. PubMed ID: 23714970 [TBL] [Abstract][Full Text] [Related]
26. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021 [TBL] [Abstract][Full Text] [Related]
27. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions? Klepin HD; Hurd DD Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209 [TBL] [Abstract][Full Text] [Related]
28. Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study. Molcho S; Peer A; Berg T; Futerman B; Khamaisi M J Clin Endocrinol Metab; 2013 Nov; 98(11):E1807-12. PubMed ID: 24037883 [TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. Fortuna G; Ruoppo E; Pollio A; Aria M; Adamo D; Leuci S; Orabona GD; Mignogna MD J Oral Pathol Med; 2012 Mar; 41(3):222-8. PubMed ID: 22092390 [TBL] [Abstract][Full Text] [Related]
30. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. Soydan SS; Uckan S J Oral Maxillofac Surg; 2014 Feb; 72(2):322-6. PubMed ID: 24075235 [TBL] [Abstract][Full Text] [Related]
31. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. Thumbigere-Math V; Sabino MC; Gopalakrishnan R; Huckabay S; Dudek AZ; Basu S; Hughes PJ; Michalowicz BS; Leach JW; Swenson KK; Swift JQ; Adkinson C; Basi DL J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928 [TBL] [Abstract][Full Text] [Related]
32. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574 [TBL] [Abstract][Full Text] [Related]
33. [The rare case of osteonecrosis of the jaws in a patient treated with bisphosphonates for osteoporosis]. Lewandowski B; Brodowski R; Kość T; Migut M; Wojnar J Przegl Lek; 2016; 73(1):46-8. PubMed ID: 27120948 [TBL] [Abstract][Full Text] [Related]
34. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033 [TBL] [Abstract][Full Text] [Related]
36. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. Dodson TB J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814 [TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-related osteonecrosis of the jaws: analysis of a case series at a dental school. Mathias Duarte LF; dos Reis HB; Tucci R; Dib LL Spec Care Dentist; 2014; 34(2):77-83. PubMed ID: 23875734 [TBL] [Abstract][Full Text] [Related]
38. [Bisphosphonate-associated osteonecrosis of the jaw]. Koy S; Schubert M; Koy J; Ney M; Lauer G; Sabatowski R Schmerz; 2015 Apr; 29(2):171-8. PubMed ID: 25860198 [TBL] [Abstract][Full Text] [Related]
39. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates. Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526 [TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database. de Boissieu P; Gaboriau L; Morel A; Trenque T Fundam Clin Pharmacol; 2016 Oct; 30(5):450-8. PubMed ID: 27315575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]